Company news

Monte Rosa Therapeutics, Inc. news in 2024

Monte Rosa Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors

December 12, 2024

Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

December 10, 2024

Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors

December 4, 2024

Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

November 6, 2024

Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

October 27, 2024

Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors

October 22, 2024

Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study

August 18, 2024

Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

August 7, 2024

Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160

June 26, 2024

Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis

June 13, 2024

Monte Rosa Therapeutics Announces Leadership Team Promotions

May 29, 2024

Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease

May 20, 2024

Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering

May 15, 2024

Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024

Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer

May 1, 2024

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

March 13, 2024

Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor

March 10, 2024

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024

January 7, 2024

Decks in 2024